Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of ...
Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...
Community driven content discussing all aspects of software development from DevOps to design patterns. Ready to develop your first AWS Lambda function in Python? It really couldn’t be easier. The AWS ...
The federal government is looking for researchers who can, in 5 years, develop stem cell treatments to repair brain damage caused by stroke, neurodegeneration, and trauma. The Functional Repair of ...
The Advanced Research Projects Agency for Health (ARPA-H), an agency within the Department of Health and Human Services, on Thursday unveiled the Functional Repair of Neocortical Tissue (FRONT) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback